Dr. Jennifer B. Valerin
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Studies Pancreatic Cancer
Studies Cancer
17 reported clinical trials
32 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
BRCA1 positive
BRCA2 positive
2Cancer
Stage IV
BRAF positive
CD4 count positive
Affiliated Hospitals
Clinical Trials Jennifer B. Valerin is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
More about Jennifer B. Valerin
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Jennifer B. Valerin has experience with
- Nivolumab
- Nab Paclitaxel
- Pembrolizumab
- Olaparib
- Gemcitabine
- Fluorouracil
Breakdown of trials Jennifer B. Valerin has run
Pancreatic Cancer
Cancer
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer B. Valerin specialize in?
Jennifer B. Valerin focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are BRCA1 positive.
Is Jennifer B. Valerin currently recruiting for clinical trials?
Yes, Jennifer B. Valerin is currently recruiting for 13 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Jennifer B. Valerin has studied deeply?
Yes, Jennifer B. Valerin has studied treatments such as Nivolumab, Nab paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with Jennifer B. Valerin?
Apply for one of the trials that Jennifer B. Valerin is conducting.
What is the office address of Jennifer B. Valerin?
The office of Jennifer B. Valerin is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.